{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:50Z","timestamp":1786118930889,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/iae.0b013e31817e100f","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T08:00:13Z","timestamp":1220428813000},"page":"1151-1158","source":"Crossref","is-referenced-by-count":57,"title":["SURVEILLANCE FOR POTENTIAL ADVERSE EVENTS ASSOCIATED WITH THE USE OF INTRAVITREAL BEVACIZUMAB FOR RETINAL AND CHOROIDAL VASCULAR DISEASE"],"prefix":"10.1097","volume":"28","author":[{"given":"LISA J.","family":"WONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAJEN U.","family":"DESAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ATUL","family":"JAIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID","family":"FELICIANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DARIUS M.","family":"MOSHFEGHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEVEN R.","family":"SANISLO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARK S.","family":"BLUMENKRANZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States.","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R2-18-20210130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States.","volume":"122","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R3-18-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-18-20210130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"R5-18-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-18-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R7-18-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R8-18-20210130","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases.","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R9-18-20210130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/08820530701420082","article-title":"Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.","volume":"22","author":"Quiroz-Mercado","year":"2007","journal-title":"Semin Ophthalmol"},{"key":"R10-18-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES).","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-18-20210130","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jama.297.14.1538","article-title":"Study aims to clarify efficacy, safety of eye drug treatments.","volume":"297","author":"Mitka","year":"2007","journal-title":"JAMA"},{"key":"R12-18-20210130","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.06-0433","article-title":"Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.","volume":"47","author":"Costa","year":"2006","journal-title":"Invest Ophthalmol"},{"key":"R13-18-20210130","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R14-18-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R15-18-20210130","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0161-6420(99)90342-1","article-title":"Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older.","volume":"106","author":"Grover","year":"1999","journal-title":"Ophthalmology"},{"key":"R16-18-20210130","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1167\/iovs.05-0981","article-title":"Visual acuities \u201chand motion\u201d and \u201ccounting fingers\u201d can be quantified with the Freiburg Visual Acuity Test.","volume":"106","author":"Schultz-Bonsel","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-18-20210130","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R18-18-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R19-18-20210130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":"Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"key":"R20-18-20210130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/IAE.0b013e3180cc2612","article-title":"Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.","volume":"27","author":"Chan","year":"2007","journal-title":"Retina"},{"key":"R21-18-20210130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/IAE.0b013e3180a032db","article-title":"Tears of the retinal pigment epithelium: an old problem in a new era.","volume":"27","author":"Chang","year":"2007","journal-title":"Retina"},{"key":"R22-18-20210130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/IAE.0b013e3180cc2645","article-title":"Retinal pigment epithelium tears after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"27","author":"Ronan","year":"2007","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200809000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:25Z","timestamp":1786035865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200809000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e31817e100f","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}